Clinical Trials for Skin Infections

Currently registered clinical trials for Skin Infections from ClinicalTrials.gov. 25 recruiting, 50 total studies.

This content is for informational purposes only. Always consult a healthcare professional.

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Skin Infections from the ClinicalTrials.gov database.

Trial Summary

  • Total studies: 50
  • Recruiting: 25
  • Active, not recruiting: 8
  • Completed: 7
  • Other: 10

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT00001230 — Host Response to Infection and Treatment in Filarial Diseases

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment500
Study TypeOBSERVATIONAL
ConditionsFilariasis; Helminthiasis; Parasitic Infection; Mansonelliasis; Onchocerciasis
Interventions

This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment. Filarial infections are caused by parasitic worms. The immature worm (larva) is transmitted to a person through a mosquito bite and grows in the human body to 2 to 4 inches in length. Althou…

NCT00344188 — Diagnosis and Treatment of Leishmania Infections

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment289
Study TypeOBSERVATIONAL
ConditionsLeishmaniasis; Skin Diseases, Parasitic; Euglenozoa Infections; Parasitic Diseases

This study will examine the natural history of Leishmanial infections and their treatments. It will provide an opportunity for NIAID staff to learn more about leishmaniasis and perhaps to improve diagnostic tests for these infections. Patients between 2 and 80 years of age with known or suspected leishmaniasis are eligible for this study.

Participants will have routine blood tests and a biopsy…

NCT00032513 — Genetic Studies of Chronic Active Epstein-Barr Disease

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment300
Study TypeOBSERVATIONAL
ConditionsChronic Active Epstein-Barr Virus

Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes infectious mononucleosis. It has also been associated with certain forms of cancer. Chronic Epstein-Barr virus (CAEBV) is a rare disease, primarily of children and you…

NCT02193295 — Reversal of Lipid-Induced Insulin Resistance

StatusRecruiting
PhaseN/A
SponsorYale University
Enrollment250
Study TypeINTERVENTIONAL
ConditionsInsulin Resistance; NAFLD
Interventions

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes.

Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydro…

NCT01011712 — The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment600
Study TypeOBSERVATIONAL
ConditionsEBV; HSV; VZV; HPV; CMV

Background:

  • Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive st…

NCT00967785 — A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment20
Study TypeINTERVENTIONAL
ConditionsLeukopenia; Neutropenia; Infections; Warts; Myelokathexis
Interventions

Background:

  • WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive function of this receptor causes mature neutrophils (part of the white blood cells) to be retained within the bone marrow rather than being released to the blood and is one of the causes of severe …

NCT01306084 — Viral Infections in Healthy and Immunocompromised Hosts

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment1000
Study TypeOBSERVATIONAL
ConditionsAnogenital Herpes; COVID-19; Herpes Labialis

Background:

- Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems. A better understanding of these new virus strains (such as SARS-CoV-2, the virus that causes COVID-19) may help to control and prevent these infections. In particular, so…

StatusRecruiting
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment600
Study TypeOBSERVATIONAL
ConditionsGATA2 Deficiency

Background:

- GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it. Others can have a wide range of health problems, from skin problems, to hearing loss, to cancer. These problems can happen at any age. Researchers want to study GATA2 deficiency to better understand …

NCT04344119 — Assessment of Chilbains Occuring During Covid-19 Infection

StatusRecruiting
PhaseN/A
SponsorCentre Hospitalier Universitaire de Nice
Enrollment30
Study TypeOBSERVATIONAL
ConditionsSkin Manifestations; COVID; Chilblains

Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. …

NCT04975152 — Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

StatusRecruiting
PhasePhase 1
SponsorH. Lee Moffitt Cancer Center and Research Institute
Enrollment36
Study TypeINTERVENTIONAL
ConditionsMerkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma
Interventions

The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).

NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorMayo Clinic
Enrollment132
Study TypeINTERVENTIONAL
ConditionsAnatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8
Interventions; ;

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals’ tumor cells. Immunotherapy with monoclonal antibodies, such as …

NCT06481163 — Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)

StatusRecruiting
PhasePhase 2
SponsorBarwon Health
Enrollment200
Study TypeINTERVENTIONAL
ConditionsBuruli Ulcer
Interventions

The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included.

• Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until …

NCT07659769 — Global Healthcare Study on Hidradenitis Suppurativa

StatusRecruiting
PhaseN/A
SponsorJulia Tatjana Maul
Enrollment9600
Study TypeOBSERVATIONAL
ConditionsHidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa)

The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare deliver…

NCT06855498 — Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

StatusRecruiting
PhasePhase 3
SponsorIncyte Corporation
Enrollment600
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa (HS)
Interventions

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

NCT06921850 — A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 3
SponsorUCB Biopharma SRL
Enrollment40
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

NCT07115043 — A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorAstraZeneca
Enrollment60
Study TypeINTERVENTIONAL
ConditionsMelanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma (Skin); Renal Cell Carcinoma; Merkel Cell Carcinoma
Interventions;

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07049575 — Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 1
SponsorIncyte Corporation
Enrollment24
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients

StatusRecruiting
PhaseN/A
SponsorNovartis Pharmaceuticals
Enrollment142
Study TypeOBSERVATIONAL
ConditionsHidradenitis Suppurativa

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 2
SponsorSanofi
Enrollment144
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions;

This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa.

The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe …

NCT07000110 — Anifrolumab Malignancy and Serious Infections Study

StatusRecruiting
PhaseN/A
SponsorAstraZeneca
Enrollment3195
Study TypeOBSERVATIONAL
ConditionsSystemic Lupus Erythematosus
Interventions

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 2
SponsorIncyte Corporation
Enrollment40
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa (HS)
Interventions

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

NCT07660354 — Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

StatusRecruiting
PhaseN/A
SponsorOystershell NV
Enrollment98
Study TypeINTERVENTIONAL
ConditionsLice; Head Lice
Interventions

To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice

NCT07387198 — Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

StatusRecruiting
PhasePhase 2
SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Enrollment135
Study TypeINTERVENTIONAL
ConditionsMerkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Neoadjuvant Immunotherapy
Interventions;

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

NCT07686913 — Steri-Strip Application Versus Standard Wound Closure for Cesarean Section Incisions

StatusRecruiting
PhaseN/A
SponsorRiverside University Health System Medical Center
Enrollment610
Study TypeINTERVENTIONAL
ConditionsCesarean Section; Surgical Site Infection; Wound Dehiscence; Seroma
Interventions;

This study is evaluating whether Steri-Strips® provide additional benefits when used after cesarean section (C-section) surgery. Steri-Strips are adhesive strips that are commonly placed over a surgical incision to provide support while the wound heals. At our hospital, Steri-Strips are routinely used after C-sections in addition to standard wound closure techniques, although they are not consi…

NCT07524062 — The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery

StatusRecruiting
PhaseN/A
SponsorUniversitaire Ziekenhuizen KU Leuven
Enrollment120
Study TypeINTERVENTIONAL
ConditionsWound Healing; Surgical Wound Infection; Postoperative Complications; Skin Neoplasms; Skin Transplantation
Interventions

This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.

Active, Not Recruiting

NCT04901195 — A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

StatusActive, not recruiting
PhasePhase 3
SponsorUCB Biopharma SRL
Enrollment658
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

NCT05632601 — Reexamining Her Cardiovascular Risk - Ottawa WomeN’s Longitudinal Cohort Study

StatusActive, not recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Enrollment176
Study TypeINTERVENTIONAL
ConditionsCardiovascular Diseases
Interventions

The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary revascularization, stroke, total and cardiovascular mortality). This future study will be the first longitudinal cohort study, to our knowledge, that is focused entirely o…

NCT06002685 — Partners in Children’s Health (CSN): A Randomized Trial of an Attachment Based Intervention

StatusActive, not recruiting
PhaseN/A
SponsorUniversity of Maryland, Baltimore
Enrollment260
Study TypeINTERVENTIONAL
ConditionsRespiratory Disease; Inflammation; Insufficient Sleep; Digestive Disease; Skin Conditions
Interventions;

The goal of this randomized controlled trial is to evaluate the impacts of an attachment-based intervention (Attachment Biobehavioral Catch-Up (ABC) and Home Book-of-the-Week (HBOW) program on emerging health outcomes (i.e., common childhood illnesses, body mass index, and sleep) in low-income Latino children (N=260; 9 months at enrollment). It is hypothesized that children randomized to ABC wi…

NCT06046729 — A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

StatusActive, not recruiting
PhasePhase 2
SponsorEli Lilly and Company
Enrollment352
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions;

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

NCT05947500 — Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

StatusActive, not recruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment50
Study TypeINTERVENTIONAL
ConditionsClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma
Interventions; ;

This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, w…

NCT06468228 — A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

StatusActive, not recruiting
PhasePhase 3
SponsorAbbVie
Enrollment1400
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions;

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe …

NCT06993610 — Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

StatusActive, not recruiting
PhasePhase 2
SponsorZura Bio Inc
Enrollment225
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa (HS)
Interventions; ;

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

NCT06958211 — Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

StatusActive, not recruiting
PhasePhase 3
SponsorIncyte Corporation
Enrollment573
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions;

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Not Yet Recruiting

NCT07668713 — FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study

StatusNot yet recruiting
PhasePhase 1
SponsorUniversity Hospital, Clermont-Ferrand
Enrollment24
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa (HS); Fecal Microbiota Transplantation (FMT)
Interventions

The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn’s disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chro…

NCT07668999 — A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes

StatusNot yet recruiting
PhasePhase 1
SponsorSinomune Pharmaceutical Co., Ltd
Enrollment64
Study TypeINTERVENTIONAL
ConditionsTinea Pedis
Interventions; ;

This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes. The study will evaluate the safety, local tolerability, and pharmacokinetic profile of two concentrations of ZYG24004 (1% and 3%) after topical administration once or twice (once weekly for two consecutive weeks), and will explore preliminary efficacy.

NCT07665437 — An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

StatusNot yet recruiting
PhasePhase 3
SponsorNovartis Pharmaceuticals
Enrollment710
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

NCT07240649 — Emerging Indications for Hyperbaric Oxygen Treatment

StatusNot yet recruiting
PhasePhase 4
SponsorJay C. Buckey Jr.
Enrollment100
Study TypeINTERVENTIONAL
ConditionsPost-COVID-19 Condition; Ulcerative Colitis; Crohn Disease; Calciphylaxis; Frostbite
Interventions;

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The re…

NCT07689188 — Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

StatusNot yet recruiting
PhasePhase 2
SponsorHarrison Dermatology
Enrollment10
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa (HS)
Interventions

This study investigates the efficacy of topical roflumilast foam in patients with HS.

NCT07665476 — Naproxen Versus Placebo as Adjunct Treatment of Cellulitis

StatusNot yet recruiting
PhasePhase 3
SponsorOttawa Hospital Research Institute
Enrollment884
Study TypeINTERVENTIONAL
ConditionsCellulitis; Skin Disease, Infectious; Infection; Skin and Soft Tissue Infections (SSTIs)
Interventions; ;

Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients’ quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID…

NCT07675239 — Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail

StatusNot yet recruiting
PhasePhase 4
SponsorPak Emirates Military Hospital
Enrollment60
Study TypeINTERVENTIONAL
ConditionsTinea Corporis
Interventions;

Tinea corporis and tinea cruris are common superficial fungal infections that have become increasingly difficult to treat because of prolonged disease duration, frequent recurrences, and suboptimal response to standard antifungal therapy. Itraconazole is widely used for the treatment of dermatophytosis; however, treatment failures and relapses remain a significant concern. Isotretinoin has been…

NCT07690319 — A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

StatusNot yet recruiting
PhaseN/A
SponsorNovartis Pharmaceuticals
Enrollment186
Study TypeOBSERVATIONAL
ConditionsHidradenitis Suppurativa

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information…

Completed Trials

NCT00353158 — A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

StatusCompleted
PhasePhase 1
SponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Enrollment62
Study TypeINTERVENTIONAL
ConditionsHealthy Volunteers; Fungal Infections; Bacterial Infections
Interventions;

This study will examine the phototoxicity, a reaction to light that is like exaggerated sunburn, which occurs in people who take medications such as voriconazole, a medication used to fight fungus. Sunscreens might protect the skin from the reaction. Although phototoxicity from voriconazole is not completely understood, it may be related to how that medication is metabolized in the liver by enz…

NCT02231879 — Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

StatusCompleted
PhasePhase 2 / Phase 3
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment20
Study TypeINTERVENTIONAL
ConditionsMyelokathexis; Infections; Neutropenia; Warts; Hypogammaglobulinemia
Interventions;

Background:

- WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.

Objective:

- To compare plerixafor versus granulocyte colony stimulating factor (G-CSF) for preventing infections in people with WHIMS.

Eligibility:

- People ages 10…

NCT04926922 — PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

StatusCompleted
PhaseN/A
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment200
Study TypeOBSERVATIONAL
ConditionsTuberculosis; HIV

Background:

Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster. TB is a leading cause of death among people in the West African country of Liberia. Researchers want to find an effective testing method for latent tuberculosis infection (LTBI) t…

NCT05764876 — Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

StatusCompleted
PhasePhase 3
SponsorFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Enrollment384
Study TypeINTERVENTIONAL
ConditionsYaws; Cutaneous Ulcer
Interventions;

The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws . The main questions it aims to answer are: can linezolid cure active yaws, and can linezolid cure latent yaws. Participants with serologically confirmed yaws will be randomized to receive linezolid (experimental) or azithromycin (control group) treatment and followed u…

NCT06175013 — Evaluation of a Combination of Two Medical Devices and One Device Use in the Treatment of Toenail Onychomycosis

StatusCompleted
PhaseN/A
SponsorSwiss Footcare Laboratories - Poderm Professional
Enrollment44
Study TypeINTERVENTIONAL
ConditionsOnychomycosis
Interventions;

The goal of this clinical investigation is to evaluate the efficacy of the tested products in medium to moderate onychomycosis after 112 days of treatments.

The main question it aims to answer is the effectiveness of the use of a combination of two investigational devices (Sérum PURIFIANT + Sérum BOOSTER) on the percentage of healthy nail surface after 112 days of treatment.

Participants will…

NCT07338773 — Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot

StatusCompleted
PhasePhase 4
SponsorBaşakşehir Çam & Sakura City Hospital
Enrollment40
Study TypeINTERVENTIONAL
ConditionsDiabetic Foot Disease; Diabetic Foot Infection; Diabetic Amputation Foot Wound
Interventions;

This randomized clinical trial compared two routes of vancomycin administration in patients undergoing below-knee amputation for ischemic diabetic foot infection. Patients with diabetic foot infection and impaired lower-extremity circulation may have reduced delivery of intravenously administered antibiotics to the amputation stump. Intraosseous administration may increase local antibiotic expo…

NCT07673484 — Tattooing and Piercing Among Medical Students

StatusCompleted
PhaseN/A
SponsorBiruni University
Enrollment180
Study TypeOBSERVATIONAL
ConditionsKeloid; Tattoo; Infection; Scar; Allergic Contact Dermatitis

The aim of this study is to evaluate medical students’ attitudes towards tattoos and piercings and to measure their awareness of associated dermatological risks.

Other (Terminated)

NCT04067219 — SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients.

StatusTerminated
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Enrollment123
Study TypeINTERVENTIONAL
ConditionsHIV-1-infection; Marker; Structural
Interventions

this study consists of the study of markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.

NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

StatusTerminated
PhasePhase 2
SponsorInsmed Incorporated
Enrollment214
Study TypeINTERVENTIONAL
ConditionsHidradenitis Suppurativa
Interventions;

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.